Skip to main content
. 2017 Feb 24;129(18):2519–2525. doi: 10.1182/blood-2017-01-761726

Figure 1.

Figure 1. Representative Sanger sequencing traces for patients with BTKCys481 variants. (A) Sanger sequencing traces on CD19-sorted BM cells showing BTKCys481Arg(c.1634T>C) and BTKCys481Ser(c.1634T>A) variants in patients WM2 and WM3, respectively. (B) Representative Sanger sequencing traces from cloning and sequencing studies show the presence of multiple BTKCys481 variants in patient WM2. Cloning and sequencing analysis showed 17/107 (15.9%), 21/107 (19.6%), and 7/107 (6.5%) clones expressed BTKCys481Arg(c.1634T>C), BTKCys481Ser(c.1634T>A), and BTKCys481Ser(c.1635G>C), respectively, for patient WM2; whereas 2/119 (1.7%), 46/119 (38.7%), and 8/119 (6.7%) clones expressed BTKCys481Arg(c.1634T>C), BTKCys481Ser(c.1634T>A), and BTKCys481Ser(c.1635G>C), respectively, for patient WM3. Arrows denote nucleotide variants. HD, healthy donor.

Representative Sanger sequencing traces for patients with BTKCys481variants. (A) Sanger sequencing traces on CD19-sorted BM cells showing BTKCys481Arg(c.1634T>C) and BTKCys481Ser(c.1634T>A) variants in patients WM2 and WM3, respectively. (B) Representative Sanger sequencing traces from cloning and sequencing studies show the presence of multiple BTKCys481 variants in patient WM2. Cloning and sequencing analysis showed 17/107 (15.9%), 21/107 (19.6%), and 7/107 (6.5%) clones expressed BTKCys481Arg(c.1634T>C), BTKCys481Ser(c.1634T>A), and BTKCys481Ser(c.1635G>C), respectively, for patient WM2; whereas 2/119 (1.7%), 46/119 (38.7%), and 8/119 (6.7%) clones expressed BTKCys481Arg(c.1634T>C), BTKCys481Ser(c.1634T>A), and BTKCys481Ser(c.1635G>C), respectively, for patient WM3. Arrows denote nucleotide variants. HD, healthy donor.